Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Atkins

Showing results (321-330 of 493) with videos related to

Pageof 50
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinomaMichael B Atkins, Manuel Hidalgo, Walter M Stadler, et al.
Journal for Immunotherapy of Cancer|May 3, 2023
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designsTian Zhang, Patrick M Forde, Ryan J Sullivan, et al.
Scientific Reports|April 27, 2019
Warmer waters masculinize wild populations of a fish with temperature-dependent sex determinationJ L Honeycutt, C A Deck, S C Miller, et al.
The Oncologist|September 10, 2008
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinibMario E Lacouture, Shenhong Wu, Caroline Robert, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2009
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinomaDaniel C Cho, Igor Puzanov, Meredith M Regan, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 26, 2007
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinomaDavid E Avigan, Baldev Vasir, Daniel J George, et al.
Science Advances|October 25, 2023
Inhibition of neutrophil extracellular trap formation alleviates vascular dysfunction in type 1 diabetic miceChao Liu, Srilakshmi Yalavarthi, Ajay Tambralli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanomaRichard W Joseph, Ryan J Sullivan, Robyn Harrell, et al.
Urologic Oncology|May 11, 2010
Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinomaAymen A Elfiky, Daniel C Cho, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2015
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805Naomi B Haas, Judith Manola, Bonnie Ky, et al.
Pageof 50

Showing results (321-330 of 493) with videos related to

Sort By:
Pageof 50
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinomaMichael B Atkins, Manuel Hidalgo, Walter M Stadler, et al.
Journal for Immunotherapy of Cancer|May 3, 2023
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designsTian Zhang, Patrick M Forde, Ryan J Sullivan, et al.
Scientific Reports|April 27, 2019
Warmer waters masculinize wild populations of a fish with temperature-dependent sex determinationJ L Honeycutt, C A Deck, S C Miller, et al.
The Oncologist|September 10, 2008
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinibMario E Lacouture, Shenhong Wu, Caroline Robert, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2009
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinomaDaniel C Cho, Igor Puzanov, Meredith M Regan, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 26, 2007
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinomaDavid E Avigan, Baldev Vasir, Daniel J George, et al.
Science Advances|October 25, 2023
Inhibition of neutrophil extracellular trap formation alleviates vascular dysfunction in type 1 diabetic miceChao Liu, Srilakshmi Yalavarthi, Ajay Tambralli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanomaRichard W Joseph, Ryan J Sullivan, Robyn Harrell, et al.
Urologic Oncology|May 11, 2010
Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinomaAymen A Elfiky, Daniel C Cho, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2015
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805Naomi B Haas, Judith Manola, Bonnie Ky, et al.
Pageof 50